Q2 2025 Viatris Inc Earnings Call Transcript
Key Points
- Viatris Inc (VTRS) achieved 3% divestiture-adjusted operational revenue growth, driven by strength in Europe and Greater China.
- The company reported positive results from five out of six anticipated Phase III readouts, including significant progress in their ophthalmology programs.
- Viatris Inc (VTRS) returned over $630 million to shareholders, including $350 million in share repurchases, demonstrating a strong commitment to shareholder returns.
- The company is making progress on its enterprise-wide strategic review, aiming to position itself for sustainable growth in 2026 and beyond.
- Viatris Inc (VTRS) is advancing its late-stage pipeline with promising candidates like meloxicam, which could tap into the $80 billion US acute pain market.
- Total revenues for the quarter were down approximately 2% versus the prior year, impacted by the Indore facility issues.
- The North American business decreased 11% year-over-year, primarily due to the Indore Impact and competition on key products.
- The Japanese market faced challenges with a decrease in net sales by approximately 11%, driven by government price regulations and competition.
- The company's gross margin was impacted by the Indore facility issues and price regulations in Japan.
- Potential US tariffs could impact the broader pharmaceutical landscape, although Viatris Inc (VTRS) does not anticipate a material effect on its 2025 financials.
Good day, everyone, and welcome to the Viatris second-quarter 2025 earnings conference call. (Operator Instructions). Please also note, today's event is being recorded. At this time, I would like to turn the floor over to Bill Szablewski, Head of Investor Relations. Sir, please go ahead.
Good morning, everyone. Welcome to our Q2 2025 earnings call. With us today is our CEO, Scott Smith; CFO, Doretta Mistras; Chief R&D Officer, Philippe Martin; and Chief Commercial Officer, Corinne Le Goff. During today's call, we will be making forward-looking statements on a number of matters, including our financial guidance for 2025 and various strategic initiatives. These statements are subject to risks and uncertainties.
We will also be referring to certain actual and projected non-GAAP financial measures. Please refer to today's slide presentation and our SEC filings for more information, including reconciliations of those non-GAAP measures to the most directly comparable GAAP measures.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
